Imedex: Education is the Best Medicine®

QUICK POLL

Which of the following statements regarding smoldering multiple myeloma (SMM) is NOT correct?

1. The diagnosis of SMM requires a serum M-protein of at least 3gm/dL and/or a bone marrow clonal plasma cell population of at least 10%
2. No CRAB (hypercalcemia, renal impairment, anemia or bone lesions) factors can be present
3. The risk of progression to active multiple myeloma is significantly higher than for monoclonal gammopathy of undetermined significance (MGUS) at approximately 5% per year over the first 10 years, and then 3% per year for the next 10 years.
4. The cumulative risk of progression at 15 years of follow-up is 73%.
5. At diagnosis, significant risk factors for progression include the serum level and type of monoclonal protein, presence of urinary light chains, the extent of marrow involvement, and reduction of uninvolved immunoglobulins.

14th Annual Perspectives in Thoracic Oncology

November 20-21, 2009

New York, New York

The Westin New York at Times Square

Continuing Medical Education
ACCME Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 12.25 of AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pulmonologists, pathologists and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with thoracic malignancies.

Objectives
Upon completion of this activity, participants should be able to:

Describe the evolving epidemiology of lung cancer and comment on the current status of women and lung cancer
Discuss surgical issues and controversies related to treatment of thoracic cancers
Evaluate the role of stereotactic radiotherapy and image-guided radiation therapy in NSCLC, focusing on the benefits and limitations of each
Recommend the most appropriate adjuvant therapy regimen for NSCLC, including selecting patients for therapy and predicting benefit
Outline management strategies for esophageal cancer, mesothelioma, and small cell lung cancer
Identify controversies in management of locally advanced NSCLC
Analyze available and emerging treatment options in advanced NSCLC, including maintenance therapy and third-line therapy and beyond
Discuss areas of therapeutic neglect in lung cancer and recommend management strategies for pleural effusion, brain metastases, and toxicities from combined modality therapy
Evaluate the emerging role of targeted therapies and immunomodulators as monotherapy and in combination with established regimens for the treatment of NSCLC
Comment on the appropriate use of biomarkers guiding the therapeutic decision-making process in patients with NSCLC

Chandra P. Belani, MD
Penn State Hershey Cancer Institute
Hershey, Pennsylvania

Jeffrey D. Bradley, MD
Washington University School of Medicine
St. Louis, Missouri

Paul A. Bunn, Jr
University of Colorado Cancer Center
Aurora, Colorado

Hak Choy, MD
University of Texas South Western
Dallas, Texas

Roger B. Cohen, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Walter J. Curran, MD, FACR
Emory Winship Cancer Institute
Atlanta, Georgia

Jessica S. Donington, MD
Stanford University School of Medicine
Stanford, California

Afshin N. Dowlati, MD
Case Western Reserve University
Cleveland, Ohio

David S. Ettinger, MD
Johns Hopkins University School
of Medicine
Baltimore, Maryland

Tracey L. Evans, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Elizabeth Gore, MD
Medical College of Wisconsin
Milwaukee, Wisconsin

Nasser H. Hanna, MD
Indiana University School of Medicine
Indianapolis, Indiana

Karen L. Kelly, MD
The University of Kansas Cancer Center
Kansas City, Kansas

Edward S. Kim, MD
University of Texas
MD Anderson Cancer Center
Houston, Texas

Hedy L. Kindler, MD
University of Chicago Medical Center
Chicago, Illinois

Brian E. Lally, MD
University of Miami Miller School of Medicine
Miami, Florida

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

R. Nevin Murray, MD
British Columbia
Cancer Agency
Vancouver,
British Columbia, Canada

Howard Safran, MD
Miriam Hospital
Providence, Rhode Island

Walter J. Scott, MD, FACS
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Joseph B. Shrager, MD
Stanford University School of Medicine
Stanford, California

Gerard A. Silvestri, MD, MS
Medical University of South Carolina
Charleston, South Carolina

George R. Simon, MD, FACP, FCCP
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Mark Socinski, MD
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Daniel H. Sterman, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Gary M. Strauss, MD, MPH
Tufts Medical Center
Boston, Massachusetts

Michael Unger, MD, FACP, FCCP
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Maria Werner-Wasik, MD
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Antoinette J. Wozniak, MD, FACP
Wayne State University
Detroit, Michigan

Friday, November 20, 2009

Session I: Introductory lectures

8:00 am
Welcome
Corey J. Langer, MD, FACP

8:05 am
Keynote lecture: Lung cancer – evolving epidemiology, risk factors, and molecular genetics
Paul A. Bunn, Jr, MD

8:30 am
Women and lung cancer: Is it now epidemic, and should women be treated differently?
Jessica S. Donington, MD

8:55 am
Creation of an epidemic: The tobacco industry and smoking related adenocarcinoma of the lung
Gary M. Strauss, MD, MPH

9:15 am
Panel discussion

9:30 am
Break

Session II: Surgery and staging

9:50 am
Case presentation: Ongoing research issues in surgery

More is better
Joseph B. Shrager, MD

Less is better
Walter J. Scott, MD, FACS

10:20 am
Cost-effective staging in NSCLC
Gerard A. Silvestri, MD, MS

10:40 am
Interventional bronchoscopy for the management of endobronchial lesions
Michael Unger, MD, FACP, FCCP

11:00 am
Panel discussion

11:15 am
Lunch

Session III: Radiation oncology for the uninitiated and perpetually perplexed

12:45 pm
V20 and other therapeutic parameters: What are they and how do we accommodate them?
Walter J. Curran, MD, FACR

1:05 pm
Stereotactic radiation: Emerging role in localized lung cancer
Hak Choy, MD

1:25 pm
Image-guided radiation therapy: Therapeutic implications and limitations
Jeffrey D. Bradley, MD

1:45 pm
Is there a role for adjuvant radiotherapy in resected NSCLC?
Brian E. Lally, MD

2:05 pm
Panel discussion

2:15 pm
Break

Session IV: Adjuvant therapy

2:30 pm
Selecting the appropriate patient and the adjuvant therapeutic regimen
Gary M. Strauss, MD, MPH

2:50 pm
Ongoing clinical trials in the adjuvant arena: Where are we heading?
Tracey L. Evans, MD

3:10 pm
Neoadjuvant therapy for NSCLC: When is it useful? When is it not?
Chandra P. Belani, MD

Session V: Special topics in thoracic oncology

3:30 pm
Esophageal cancer
Howard Safran, MD

3:50 pm
Mesothelioma
Hedy L. Kindler, MD

4:10 pm
SCLC: Are we doomed to therapeutic paralysis?
David S. Ettinger, MD

4:30 pm
Panel Discussion

4:45 pm
Adjourn

Saturday, November 21, 2009

8:30 am
Welcome to day two
Corey J. Langer, MD, FACP

Session VI: Advanced NSCLC

8:40 am
First-line treatment for advanced NSCLC: What is the standard?
Antoinette J. Wozniak, MD, FACP

9:05 am
Molecular determination of cytotoxic therapy
George R. Simon, MD, FACP, FCCP

9:25 am
Maintenance therapy in advanced NSCLC: Has its time arrived?
Corey J. Langer, MD, FACP

9:45 am
Third-line therapy and beyond
Nasser H. Hanna, MD

10:10 am
Break

Session VII: Therapeutic neglect in lung cancer

10:30 am
Management of pleural effusions
Daniel H. Sterman, MD

10:50 am
Brain metastases: New therapies, new insights
Elizabeth M. Gore, MD

11:10 am
Managing the toxicities of combined modality therapy
Maria Werner-Wasik, MD

11:30 am
Panel Discussion

11:45 am
Lunch

Session VIII: Targeted therapies and immunomodulation

1:00 pm
Antibodies: Cetuximab, bevacizumab and beyond
Edward S. Kim, MD

1:20 pm
New angiogenesis inhibitors and tyrosine kinase inhibitors in the treatment of NSCLC
Karen L. Kelley, MD

1:50 pm
Vaccines: Are there realistic expectations?
Nevin Murray, MD

2:10 pm
Promising new therapies in NSCLC: HDAC inhibitors; hedgehog inhibitors, TRAIL antibodies, etc.
Roger B. Cohen, MD

2:30 pm
Panel discussion

2:50 pm
Break

Session IX: Biomarkers

3:10 pm
Debate: Which markers should we use to guide therapy?

Biomarkers
Lecia V. Sequist, MD, MPH

Clinical markers
Mark Socinski, MD

3:50 pm
Using biomarkers to predict the efficacy of antiangiogenic agents and other targeted therapies
Afshin N. Dowlati, MD

4:15 pm
Summary and adjournment
Corey J. Langer, MD, FACP

Registration Fees

Discounted $250
Payment received by September 22, 2009

Regular $350
Payment received by November 12, 2009

Full/Onsite: $450
Payment received after November 12, 2009

Group discount (Physicians only) -$50
Cannot be combined with any other discounts

Nurses/Residents/Students $99
Proof of eligibility must accompany registration

Registration Procedures

To Register: Online registration is open till November 12, 2009 or call Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

The Registration and Information Desk at the Westin New York will be staffed:
Friday, November 21
7:00 am – 5:30 pm
Saturday, November 22
7:30 am – 5:00 pm

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for Nurses/Residents/Students.

Payment: To pre-register, registration and payment must be received no later than November 12, 2009. Please register onsite after this date. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 12, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 12, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Westin New York at Times Square
270 West 43rd Street
New York, New York 10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701
www.westinny.com

The fragrant aroma of White Tea welcomes you upon arrival at The Westin New York at Times Square. Discover 863 rooms and suites with a soothing color palette and views of New York City and the Hudson River. Utilize such modern amenities as high-speed internet access with wireless connectivity available in select rooms. Note the personal touches, like the custom-designed terry bathrobe. Experience a rejuvenated transformation when you awake in Westin’s Heavenly Bed^® or step from Westin’s Heavenly Bath®.

For the convenience of attendees, a limited number of rooms have been reserved until October 29, 2009 at a discounted rate of $349 single/double occupancy, plus tax, currently at 14.25%. This rate is not guaranteed outside the conference dates or after October 29, 2009.

To reserve your room please contact the Westin New York at Times Square reservations department at +1 (212) 201 2700 or visit the hotel’s website at http://www.starwoodmeeting.com/Book/thoraciconcologyatt. To receive the group rate, callers must identify themselves as being with the Perspectives in Thoracic Oncology group. Reservation requests received after October 29, 2009 may not be guaranteed the group rate.

Dear Colleague,

Please join me in New York City this November for the 14th Annual Perspectives in Thoracic Oncology.

14 Years of Exceptional Educational Value
Perspectives in Thoracic Oncology has become the premier source for updates in thoracic oncology; we readily recognize the burgeoning need among thoracic oncology clinicians and researchers for the latest information on the complex biology and treatment of lung cancer. This conference provides a forum to update your knowledge in the field, confirm your current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.

Significant Impact on Clinical Practice
Nearly 200 physicians, nurses, and other healthcare professionals attend Perspectives in Thoracic Oncology annually. Past participants value the scope and depth of the information on disease biology, management, and research presented, and many return year after year for the newest updates.

Distinguished Faculty and Networking Opportunities
In this educational setting, you will have valuable opportunities to interact with your colleagues and learn from renowned faculty, key thought leaders in thoracic oncology, as well as network with the diverse mix of oncologists, surgeons, and pulmonologists who attend. This fall’s conference, to be held November 20-21, 2009, at the Westin New York at Times Square, promises to be our most exciting meeting yet. I hope to see you there!

Sincerely,
Chair: Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

ORGANIZER

Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

The following companies have provided educational grants in support of this conference:

GOLD

Genentech BioOncology
OSI Oncology

Lilly

SILVER

boehringer-ingleheim

CORPORATE

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

The following company is an exhibitor at this conference:

Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712 or by email at c.gunter@imedex.com.

Download the Exhibitor Manual

Information coming soon.